Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

One Lambda Obtains FDA Clearance for HLA Fusion Software Version 3.0

Published: Thursday, January 24, 2013
Last Updated: Thursday, January 24, 2013
Bookmark and Share
HLA Fusion Software version 3.0 has obtained FDA clearance by the FDA and a Health Canada License by the Ministry of Health Canada.

All of One Lambda software products are designed to assist personnel experienced in HLA analysis by suggesting typing and antibody screening results. Product families used in conjunction with HLA Fusion include the market-leading LABScreen® (antibody detection) and LABType® (HLA Typing) products, in addition to LAT™, LCT™, FlowPRA®, and MicroSSP™ products. The HLA Fusion Software version 3.0 provides all the tools and applications from version 2.0 and its related Service Packs, support with Luminex® xPONENT® 3.1 acquisition software for LABScan® 100, and more.

In response to obtaining clearance, One Lambda’s Director of Marketing, Stewart Han, expressed his excitement by saying, “We are pleased to see another great accomplishment from our software development team. Their hard work and determination has created brilliant analysis software that continues to help position our molecular typing and antibody screening products at the forefront of transplant diagnostics and improve the quality of patient life.” Gouri “GS” Jha, Director of Information Systems and Commercial Software Products also stated, “We are extremely proud to have been awarded FDA clearance for HLA Fusion software 3.0 and it is gratifying that the hard work and dedication of our team has paid off by delivering a powerful new tool for the transplant community.“

(Limitations: All One Lambda software products are designed to assist personnel experienced in HLA analysis by suggesting typing results. However, any clinical or diagnostic results must be carefully reviewed by a person qualified in HLA typing to assure correctness. This software may be used to aid in suggesting results, but should not be used as the sole method for determining reportable results. This software is meant as a laboratory aid, not as a source of definitive results. The software design does not mitigate hazards associated with the software. The laboratory director or technologist trained in histocompatibility testing is required to review all data to detect any problems with the software.)


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Small Molecules Lead to Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
Sanger Institute, St Jude Data-Sharing Agreement
Childhood cancer targeted by Sanger Institute and St Jude Children’s Research Hospital exchanges of cancer data
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Space Research Fighting Cancer
JPL and National Cancer Institute renew Big Data partnership that 'learns' data similarities.
Uncovering the Genetics Behind High Blood Pressure
Results suggest a role for blood vessels themselves in controlling blood pressure.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!